Documentation
Vendor-supplied data
COA stated as available
Not independently documented
Checked
Jul 18, 2026
Mitochondrial
Also known as: NAD Β· nicotinamide adenine dinucleotide Β· NAD plus
A coenzyme β not a peptide β central to cellular energy metabolism, promoted via IV drips and precursor supplements (NR, NMN) for anti-aging and 'wellness'. Precursors reliably raise NAD+ levels, but human evidence for the anti-aging claims is limited.
Crystal Peptides. The table lists only product-specific offers that were checked and for which a real destination exists. Missing prices, quantities, stock and laboratory details are not inferred.
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every living cell, not a peptide. It shuttles electrons in redox reactions and serves as a substrate for enzymes such as sirtuins and PARPs involved in metabolism and DNA repair. Commercially it appears as direct intravenous or injectable NAD+, and as oral precursors such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) that the body converts into NAD+.
Limited, especially for the anti-aging claims that drive sales. Trials show oral precursors such as NR and NMN can reliably raise blood NAD+ levels and are generally safe short-term, but most measured clinical outcomes β glucose and lipid metabolism, muscle strength, physical function β have not improved significantly versus placebo. Direct IV NAD+ is barely studied: small pilot work has tracked its metabolism during infusion, but no adequately powered trials support IV NAD+ for anti-aging or any wellness outcome.
Oral NR and NMN have been well tolerated in short-term trials, with generally mild side effects. Intravenous NAD+ is used at clinics but has little formal safety characterization; faster infusions are commonly associated with transient discomfort such as flushing, nausea, chest tightness, and cramping. Long-term safety of sustained NAD+ elevation in humans is not established.
NAD+ is a coenzyme, not a peptide and not an approved drug. No intravenous or injectable NAD+ product is approved by the FDA or EMA for anti-aging, cognitive, or wellness use; IV NAD+ is offered at clinics as an unapproved application. Among precursors, nicotinamide riboside (NR) is sold as a dietary supplement, whereas the US FDA has taken the position that NMN is excluded from the dietary-supplement definition.
Vendor comparison
The table lists only product-specific offers that were checked and for which a real destination exists. Missing prices, quantities, stock and laboratory details are not inferred.
Documentation
Vendor-supplied data
COA stated as available
Not independently documented
Checked
Jul 18, 2026
Affiliate disclosure: This page contains affiliate links. peptides.cx may receive a commission when a purchase is made through one of these links. Evidence ratings, safety summaries and editorial content are produced independently from vendor relationships.
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every living cell, not a peptide. It shuttles electrons in redox reactions and serves as a substrate for enzymes such as sirtuins and PARPs involved in metabolism and DNA repair. Commercially it appears as direct intravenous or injectable NAD+, and as oral precursors such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) that the body converts into NAD+.
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every living cell β not a peptide. It shuttles electrons in the redox reactions that power metabolism and serves as a required co-substrate for enzymes such as sirtuins and PARPs involved in energy production and DNA repair. Despite often being grouped with "peptide therapy" in wellness marketing, NAD+ is a fundamentally different kind of molecule. It reaches consumers in two main forms: as direct intravenous or injectable NAD+ offered at clinics, and as oral precursors such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) that the body converts into NAD+.
The honest evidence picture is that precursors do what they claim biochemically, but not much more. Trials show oral NR and NMN can reliably raise blood NAD+ levels and are generally safe in the short term, yet most measured clinical outcomes β glucose and lipid metabolism, muscle strength, physical function β have not improved significantly versus placebo. Direct intravenous NAD+ is barely studied: small pilot work has tracked its metabolism during infusion, but no adequately powered trials support IV NAD+ for anti-aging or any wellness outcome. Enthusiasm rests largely on rodent and cell studies that have not translated cleanly into human benefit, which is why the anti-aging claims driving sales outrun the data.
On safety and regulation, oral NR and NMN have been well tolerated in short-term trials, with generally mild side effects, while intravenous NAD+ has little formal safety characterization and faster infusions are commonly linked to transient flushing, nausea, chest tightness, and cramping. The long-term effects of chronically elevated NAD+ in humans are simply not established. NAD+ is not an approved drug, and no IV or injectable NAD+ product is approved by the FDA or EMA for anti-aging, cognitive, or wellness use. Among precursors, NR is sold as a dietary supplement, whereas the US FDA has taken the position that NMN is excluded from the supplement definition. This page is educational and not medical advice; it provides no dosing, administration, or sourcing guidance.
Evidence grade: C
Limited, especially for the anti-aging claims that drive sales. Trials show oral precursors such as NR and NMN can reliably raise blood NAD+ levels and are generally safe short-term, but most measured clinical outcomes β glucose and lipid metabolism, muscle strength, physical function β have not improved significantly versus placebo. Direct IV NAD+ is barely studied: small pilot work has tracked its metabolism during infusion, but no adequately powered trials support IV NAD+ for anti-aging or any wellness outcome. Preclinical studies in rodents and cell models are the main source of enthusiasm: raising NAD+ or its precursors has improved metabolic and some age-related measures in animals. However, human NAD+ dynamics differ from rodents, and these animal results have not translated cleanly into demonstrated clinical benefit in people.
Limited, especially for the anti-aging claims that drive sales. Trials show oral precursors such as NR and NMN can reliably raise blood NAD+ levels and are generally safe short-term, but most measured clinical outcomes β glucose and lipid metabolism, muscle strength, physical function β have not improved significantly versus placebo. Direct IV NAD+ is barely studied: small pilot work has tracked its metabolism during infusion, but no adequately powered trials support IV NAD+ for anti-aging or any wellness outcome.
Preclinical studies in rodents and cell models are the main source of enthusiasm: raising NAD+ or its precursors has improved metabolic and some age-related measures in animals. However, human NAD+ dynamics differ from rodents, and these animal results have not translated cleanly into demonstrated clinical benefit in people.
Oral NR and NMN have been well tolerated in short-term trials, with generally mild side effects. Intravenous NAD+ is used at clinics but has little formal safety characterization; faster infusions are commonly associated with transient discomfort such as flushing, nausea, chest tightness, and cramping. Long-term safety of sustained NAD+ elevation in humans is not established.
NAD+ is a coenzyme, not a peptide and not an approved drug. No intravenous or injectable NAD+ product is approved by the FDA or EMA for anti-aging, cognitive, or wellness use; IV NAD+ is offered at clinics as an unapproved application. Among precursors, nicotinamide riboside (NR) is sold as a dietary supplement, whereas the US FDA has taken the position that NMN is excluded from the dietary-supplement definition.